AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04762043 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reference System: Electrolarynx
Description: Hand-operated electromechanical device that operates as an artificial larynx to enable a person after laryngectomy to produce speech.
Study NCT05014464 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib 250mg po bid Aectinib 600mg po bid Lorlatinib 100mg po qd Brigatinib, 90mg po qd for one week and than 180mg po qd forever Pemetrexed 500mg/m2
Study NCT06504602 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Virtual Reality
Description: Active virtual reality group will play a game through a virtual environment.
Study NCT06504602 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passive Virtual Reality
Description: Passive virtual reality group will watch a movie through a virtual environment.
Study NCT06501768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genistein
Description: Escalation genistein dosing, followed by wash-out period
Study NCT05289180 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: A questionnaire will be administered post-procedure to assess for pain and anxiety. This questionnaire will be administered by study personnel delegated to administer questionnaires, namely the study coordinator or PI.
Study NCT05602883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music therapy
Description: Music is played for 30 minutes to the pregnant woman who is hospitalized due to the threat of premature birth.
Study NCT05679479 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meplazumab for injection
Description: Meplazumab is a humanized anti-CD147 immunoglobulin 2 (IgG2) monoclonal antibody which is expected to block the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human host-cell-expressed CD147, thereby blocking entry of SARS-CoV-2 into human tissue. This expectation is based on in vitro functional studies using Vero E6 cells infected with SARS-CoV-2 that demonstrated effective meplazumab mediated virus gene copy number inhibition upwards of 90% as evaluated by quantitative polymerase chain reaction. Meplazumab may also inhibit COVID-19 associated cytokine storm syndrome based on inhibition of the pro inflammatory factor Cyclophilin A host-cell CD147 interaction.
Study NCT04853511 — intervention group
Intervention type: DEVICE
Intervention: OCT-FLIM (optical coherence tomography-fluorescence life time)
Description: comprehensive assessment of coronary plaque with OCT-FLIM dual modal intravascular catheter imaging followed by serial 18F-FDG-PET/CT imaging
Study NCT05679479 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 0.9% normal saline
Study NCT05748756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enucleation and filling by Bone marrow aspirate
Description: The iliac crest is palpated along its widest part forming the iliac tubercle ( 5-6 cm posterior to the anterior superior iliac spine), then a 5 mm incision is made 3-4 cm posterior to the ASIS directly on the crest.~The needle is advanced between the outer and inner plates of the ileum for a 4-6 cm into the cancellous bone and 10 ml of bone marrow is aspirated.~Bone marrow aspirate is processed by a dual centrifugation technique.
Study NCT05748756 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional enucleation only
Description: patients were treated conventionally by enucleation and plain collagen sponge only.
Study NCT06101979 — intervention group
Intervention type: DEVICE
Intervention: Fortiva Tissue Matrix
Description: Acellular Dermal Matrix used in hernia surgery
Study NCT04757064 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard rehabilitation protocol
Description: they will receive knee flexion exercises and increase the extensor strength
Study NCT05612672 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GeoHAI
Description: A Geographic healthcare-associated infection (HAI) visualization and assessment tool (GeoHAI) which uses spatio-temporal Bayesian models to identify clusters of National Healthcare Safety Network (NHSN)-defined hospital onset Clostridium difficile (CDI) and multidrug resistant organisms (MDRO), and predict potential high risk areas given hospital and patient risk factors.
Study NCT04963543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FID123238
Description: Lubricant applied to the ocular surface
Study NCT05769010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: SHR-A1811: intravenous
Study NCT06034951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Compleat 1.5 HP
Description: Patients well established and stable on an enteral tube feed. This group will act as their own controls and switched to the new tube feed.
Study NCT04776187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gadodiamide
Description: Gadodiamide Injection(OMNISCAN™)
Study NCT04776187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoteric Acid Meglumine Salt
Description: Gadoteric Acid Meglumine Salt Injection(Jia Di Xian™)
Study NCT05769010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib: oral
Study NCT05769010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab: intravenous
Study NCT06546774 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: In the study group, patients will receive melatonin supplementation for at least two months prior to IVF cycles
Study NCT06173102 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cranial Orthosis
Description: Early versus usual reception of orthosis.
Study NCT06173102 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cranial Orthosis
Description: Early versus usual reception of orthosis.
Study NCT04920630 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy - Insomnia (CBT-I)
Description: CBT-I will be delivered via 5 weekly virtual group therapy sessions. Session content is manualized and adapted from existing CBT-I protocols to be relevant to a virtual adolescent group and will include: Session 1 - Introduction of group members, group rules, psychoeducation regarding sleep, and instructions on completion of sleep log. Session 2 - Review sleep log, sleep hygiene, relaxation training, and stimulus control. Session 3 - Review sleep log, sleep restriction, and cognitive strategies (positive self-statements, worry management). Session 4 - Review sleep log and sleep restriction, and problem-solving barriers. Session 5 - Maintenance and relapse prevention.
Study NCT06089928 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vertical augmentation
Description: sandwich osteotomy with an Interpositional inlay graft
Study NCT04837131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib 4 mg capsule taken orally on days 1, 8, and 15 of a 28-day treatment cycle repeated for 6 cycles
Study NCT06395454 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Shorten antibiotics duration based on procalcitonin test levels
Description: procalcitonin test will be taken on day 1 of recruitment as baseline, test done on day 5 will decide whether antibiotics will be withheld, followed by day 7 to determine rate of reinfection.
Study NCT05087212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor + G-CSF
Description: subcutaneous (SC) injection
Study NCT06232811 — intervention group
Intervention type: BEHAVIORAL
Intervention: Assessment
Description: Sensory processing skills of children in the preterm and term groups will be evaluated. Additionally, the attachment between mother and baby will be evaluated.
Study NCT06304753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telebot
Description: This is a mini-program based on a personal messenger, which is controlled by text commands in a chat on the question-answer principle. It allows us to automate data collection and obtain information about the patient's well-being and his vital signs (blood pressure, heart rate, weight) related to heart failure.~Follow-up and management of heart failure medications provided by specialists at participating institutions. Doses of oral heart failure medications optimized within 6 weeks, provided clinical assessments and laboratory measures indicate that it is safe to increase doses.
Study NCT06506188 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LINK model
Description: The LINK model includes four elements:~(1) linking postpartum HIV testing and PrEP services to early infant vaccination, (2) screening for HIV risk among those who test negative for HIV at the early infant vaccination visit, (3) male partner engagement to support status awareness within couples and PrEP persistence, and (4) community-facility linkage (CFL) peer mom for ongoing support of breastfeeding women using PrEP and follow-up of breastfeeding women who disengage from PrEP care.
Study NCT05482529 — intervention group
Intervention type: OTHER
Intervention: Integrative omics
Description: Integrative omics such as RNA-sequencing,ATAC-seq(Assay for Transposase-Accessible Chromatin using sequencing), CUT\&Tag（ Cleavage Under Targets and Tagmentation）to analyze and predict candidate biomarkers of colorectal cancer and distant metastasis.
Study NCT05571670 — intervention group
Intervention type: DRUG
Intervention: Drug-induced acute insulin resistance due to PI3K inhibitor, AKT inhibitor, or mTOR inhibitor
Description: Participants will be treated with PI3K/AKT/mTOR inhibitors by their treating oncologist based on standard of care. This study will prospectively monitor bile acids and parameters of insulin resistance before and during treatment with these drugs.
Study NCT06509282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Concurrent training
Description: Protocol:~Duration: 6 weeks. Frequency: 3 times a week. Type: Concurrent. This consists of a combination of aerobic exercise and muscular resistance exercise.~Details of the type of exercise:~Aerobic exercise:~Participants will perform 5-10 intervals per session of walking or jogging at a moderate to high intensity, with a rating of 5 to 10 points on the modified Borg scale of 1-10 points. Each interval will consist of 1 minute of walking or jogging, followed by 2 minutes of inactive pause.~Muscular resistance exercise:~Participants will perform concentric and eccentric and/or isometric contractions for 1 minute at an intensity of 5-10 according to the OMNI-RES scale. The rest period will last 2 minutes, and each exercise will be repeated 3 times. Three exercises per session will be performed: squats, push-ups, and plank.~Pharmacological treatment:~Participants will be asked to maintain their lifestyle, including taking prescribed medication as usual.
Study NCT06779396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The triamcinolone acetonide plus ropivacaine group
Description: The solution prepared comprised a mixture of 20mL of 0.2% ropivacaine(40mg) with 4 mg of triamcinolone acetonide. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
Study NCT06779396 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: The ropivacaine group
Description: The local infiltration solution containing 20mg of 1% ropivacaine. The total volume is 20 ml. The assigned solution will be injected subcutaneously by surgeons along the incision and throughout the entire thickness of the scalp before skin incision. The volume of local infiltration solution will be decided by surgeons according to the cut length, and the capacity of the solution will be recorded by investigators.
Study NCT05257460 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop using ultra-rapid insulin lispro
Description: Hybrid closed-loop using ultra-rapid insulin lispro
Study NCT05257460 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid closed-loop using standard insulin lispro
Description: Hybrid closed-loop using standard insulin lispro
Study NCT04461730 — intervention group
Intervention type: DEVICE
Intervention: deep brain stimulation
Description: Behavioral and electroencephalographic responses will be compared on and off deep brain stimulation
Study NCT04982198 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ROSA assisted TKA
Description: Robotic assisted total knee arthroplasty
Study NCT04982198 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ROSA assisted TKA
Description: Robotic assisted total knee arthroplasty
Study NCT04953468 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: expression level of ANXA2 protein
Description: The expression level of ANXA2 protein in glioma and PTBE was detected by immunohistochemistry
Study NCT06595823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betadine
Description: To compare between Betadine (10%) and saline (0.9%) in swapping of subcutaneous tissue for prevention of surgical site infection after primary elective caesarian section.
Study NCT06595823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Betadine
Description: To compare between Betadine (10%) and saline (0.9%) in swapping of subcutaneous tissue for prevention of surgical site infection after primary elective caesarian section.
Study NCT05852158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin 2 GM Injection
Description: Single pre-op dose of 2g IV cefazolin
Study NCT05852158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin Injection
Description: Pre-op dose of 2g IV cefazolin along with 3 post-op doses of 2g IV cefazolin every 8 hours
Study NCT06605612 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: FBIndex
Description: There will be no intervention.
Study NCT06607952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scenario-based case videos teaching protocol
Description: Students in the experimental group will receive a new teaching method of scenario-based case video interventions. These videos cover five key scenarios: Triage, SDH and ETTC, AMI and D2B, COPD AE and TOCC, and Sepsis and the CVC Procedure.~This teaching method is grounded in experiential learning theory and critical thinking strategies, designed to guide students in learning emergency nursing through video experiences. In each class, the instructor will first introduce the foundational concepts of emergency nursing for each system. Students will then watch a 15-minute scenario-based case video. Afterward, the instructor will facilitate a 15-minute discussion using reflection sheets to promote experiential learning and critical
Study NCT06607952 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional lecture-based teaching method
Description: Students in the control group will receive traditional lecture-based instruction on the five topics: Triage, SDH and ETTC , AMI and D2B , COPD AE and TOCC , and Sepsis and the CVC Procedure. During the lectures, the instructor will encourage students to ask questions and engage in discussions to enhance understanding.
Study NCT05233111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Prolonged Exposure Therapy
Description: Brief PE will include 3 therapy sessions, each lasting approximately 60 minutes.
Study NCT05233111 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: This may include an evaluation by a licensed psychologist and continued follow-up psychotherapy as needed. Treatment as usual participants will have follow-up assessments at 1, 3, and 6 months.
Study NCT06508125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cross-linked hyaluronic acid
Description: cross-linked hyaluronic acid injection with physical therapy
Study NCT06608667 — intervention group
Intervention type: DEVICE
Intervention: The study was retrospective and did not involve the application of interventions
Description: The study was retrospective and did not involve the application of interventions
Study NCT06608654 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: endoscope application
Description: Intrauterine bronchoscopy application for fetal distress during labor
Study NCT06608056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pain management after surgery
Description: Patients in Group A received injection tramadol 50mg intravenously every 8 hours following surgery. Patients in Group B received injection ketorolac 30mg intravenously every 8 hours following surgery.
Study NCT06606561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NANOVAE - Acellular Allogenic Human Amniotic Fluid (hAF)
Description: A total of 24 subjects meeting all inclusion/exclusion criteria will be divided into two groups. Group 1 will be an open-label lead-in phase. Group 2 will be a randomized, double-blinded, placebo-controlled cohort. Group 1 will receive one dose of 2ml of NANOVAE, and Group 2, in a randomized and double-blinded fashion, will receive two doses of 2ml NANOVAE. Neither the patients nor the researchers will know who is getting the placebo and who is getting the NANOVAE; only the product manufacturing staff will be unblinded. The ratio of placebo to NANOVAE is 1:1 for a total of 16 subjects in Group 2. Only the knee with the more severe symptoms of OA will be treated. The allogenic-HAF
Study NCT06606561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% Sodium Chloride Injection, USP
Description: In lieu of AF, the saline for injection will be used as a placebo. Vials acquired from the manufacturer is pipetted into glass vials, stoppered, capped, placed in labeled header foil pouches, and sealed. These are transferred to a quarantine freezer to await post-production testing.
Study NCT06662097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevonescein
Description: Bevonescein is a sterile solution that is intravenously administered
Study NCT06604936 — intervention group
Intervention type: OTHER
Intervention: Fibromyalgia group
Description: Demographic information (age, height, weight, occupation, medication, smoking) of the individuals who agreed to participate in the study will be recorded. Then, static and dynamic core endurance tests will be performed to evaluate core endurance. Static core endurance tests will include side bridge test, trunk flexion test, trunk extension test and prone bridge test. Modified push-ups and sit-ups tests will be performed as dynamic core endurance tests. Functional status of the patients will be evaluated with the Fibromyalgia Impact Questionnaire. Static and dynamic balance assessment will be evaluated using the HUR BTG4 Balance Master System and Berg Balance Scale.
Study NCT06604936 — intervention group
Intervention type: OTHER
Intervention: Healthy group
Description: Demographic information (age, height, weight, occupation, medication, smoking) of the individuals who agreed to participate in the study will be recorded. Then, static and dynamic core endurance tests will be performed to evaluate core endurance. Static core endurance tests will include side bridge test, trunk flexion test, trunk extension test and prone bridge test. Modified push-ups and sit-ups tests will be performed as dynamic core endurance tests. Static and dynamic balance assessment will be evaluated using the HUR BTG4 Balance Master System and Berg Balance Scale.
Study NCT06606678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: supervised exercise training; twice a week for 12 months
Study NCT06605729 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-learning
Description: The content of this e-learning is based on most recent scientific knowledge and guidelines about the management of chronic pain and physical activity and on behavioral change. Four themes are presented: chronic pain, physical activity and chronic pain, specific populations and behavior change.
Study NCT06608914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate
Description: Nandrolone will be administered to the testosterone group, specifically a 200mg dose weekly for 8 weeks beginning 2 weeks prior to surgery.
Study NCT06608914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline will be administered to the saline group, specifically a 200mg dose weekly for 8 weeks beginning 2 weeks prior to surgery.
Study NCT06608264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stress ball intervention
Description: Stress ball intervention; A medium hard, round, high quality stress ball of the same brand will be given to the patient\&amp;#39;s actively used hand 1-2 minutes before starting the continuous passive movement exercise by the researcher.The patient will be asked to squeeze and relax the stress ball for a count of 5 during continuous passive movement.After squeezing the stress ball, the patient should count to 5 and then relax it.The patient will be asked to continue this process until the continuous passive movement exercise is completed.
Study NCT06608264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hand holding intervention
Description: Hand holding intervention will be performed by the person the patient prefers. Before the continuous passive movement exercise, the person concerned will sit next to the patient\&#39;s bed and warm their hands at a level that will not disturb the patient.1-2 minutes before the continuous passive motion exercise, the patient will hold the patient\&#39;s hand with one hand, without using gloves, with moderate pressure, without rubbing or squeezing to an uncomfortable level.Hand holding intervention will continue until the continuous passive movement exercise is completed.
Study NCT06606938 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Faecal Microbiota Transplantation
Description: FMT at baseline, week 2, week 4
Study NCT06606938 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Normal Saline (Placebo)
Description: Placebo at baseline, week 2, week 4